Vaccines Shouldn't Be Big Business in Poor Countries

Page 1

VACCINES SHOULDN’T BE BIG BUSINESS IN POOR COUNTRIEs Pfizer + GSK have made over $26 billion $ on the pneumococcal $ in rich countries. $ $ $ vaccine $ $

$ $

$

$

$

$

$

$

$ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $$ $ $ $ $ $ $ $ $ $ $ $ $ $ $$ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $$ $ $ $ $ $ $

$

$ $

$

$

$

$

$

$

$

$

$

$

$

$

$1.5$ bil$lion$ do$ lla$rs

P theAoY T O rder o f

o ve r

$

$

$

$

$

$

$

$ $

BIG PHARMA

$ $ $

$

$

$

$ $$$ $ $ $ $ $ $ $ $

6

s r a l l $ 2 6 b il li o n d o Have

and the icing on top? Pharma gets another $1.5 billion taxpayerfunded subsidy on top of the vaccine price for poor countries.

y ou r cake, and eat it too.

BIG

Tell GAVI to bring vaccine prices down


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.